Elexacaftor/Tezacaftor/Ivacaftor CFTR调节剂治疗对囊性纤维化患者内镜鼻窦手术率的影响
基于TriNetX数据库2012至2023年囊性纤维化患者数据,比较使用ETI与未使用CFTR调节剂或其他CFTR调节剂患者接受功能性内镜鼻窦手术(FESS)的风险。ETI组FESS绝对风险降低显著,且术后肺急性加重和住院风险较其他调节剂组降低,提示鼻窦疾病及整体健康状况改善。
要点
- ETI组FESS绝对风险较未使用CFTR调节剂组降低2.12%(95%CI 1.5-2.75,P<0.0001)。
- ETI组FESS绝对风险较其他CFTR调节剂组降低4.7%(95%CI 3.54-5.85,P<0.0001)。
- ETI组术后6个月内肺急性加重和住院风险较其他CFTR调节剂组显著降低。
核心结论
- 在大数据集里,使用ETI的囊性纤维化患者较未使用CFTR调节剂或使用其他CFTR调节剂者,FESS、肺急性加重和住院风险显著降低,提示鼻窦疾病及整体健康状况改善。
研究设计与样本
- FESS前使用ETI者(n=6,056)按相关因素倾向性评分匹配至未使用CFTR调节剂的囊性纤维化对照(n=37,906)及使用其他FDA批准CFTR调节剂(tezacaftor/ivacaftor、lumacaftor/ivacaftor和ivacaftor)者(n=2,437)。
- 主要结局为接受FESS的绝对风险降低(ARR);次要结局为FESS后0至6、6至12、12至24个月囊性纤维化相关肺急性加重和住院的ARR。
主要发现
- ETI组较未使用CFTR调节剂组FESS的ARR为2.12%(95%CI 1.5-2.75,P<0.0001)。
- ETI组较其他CFTR调节剂组FESS的ARR为4.7%(95%CI 3.54-5.85,P<0.0001)。
- ETI组与未使用CFTR调节剂组在次要结局上无显著差异,唯FESS后0至6个月囊性纤维化相关肺急性加重减少。
- ETI组较其他CFTR调节剂组在所有时间点肺急性加重显著减少,FESS后6个月内住院显著减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI), a combination cystic fibrosis transmembrane receptor (CFTR) modulator, has demonstrated improved pulmonary outcomes in individuals with cystic fibrosis (CF). However, ETI's impact on functional endoscopic sinus surgery (FESS) remains unclear. METHODS: The TriNetX Analytics Research Network, consisting of 120 million global de-identified electronic medical records, was queried from 2012 to 2023 for subjects with CF who underwent sinus surgery.1 Patients on ETI prior to FESS (n = 6,056) were propensity score matched to control individuals with CF not on CFTR modulators (n = 37,906) and those on other FDA-approved CFTR modulators (tezacaftor/ivacaftor, lumacaftor/ivacaftor, and ivacaftor) (n = 2437) based on relevant factors. The primary outcome was the absolute risk reduction (ARR) of undergoing FESS. Secondary outcomes included ARR of CF-related pulmonary exacerbations and hospital admission from 0 to 6, 6 to 12, and 12 to 24 months following FESS. RESULTS: ETI use demonstrated a significant ARR for FESS when compared to CF patients not on CFTR modulators (2.12%; 95% confidence interval [CI] 1.5-2.75; p-value < 0.0001) and those on other CFTR modulators (4.7%; 95% CI 3.54-5.85; p-value < 0.0001). No significant differences occurred in secondary outcomes between ETI and non-CFTR modulator groups, except for reduced CF-related pulmonary exacerbations from 0 to 6 months post-FESS. Additionally, a significant reduction in pulmonary exacerbations was observed at all time points and hospital admissions within 6 months following FESS compared to those using other CFTR modulators. CONCLUSIONS: In a large dataset, CF patients on ETI demonstrated significantly reduced risk of FESS, pulmonary exacerbations, and hospital admission compared to patients not on CFTR modulators or those on other CFTR modulators, suggesting improved sinonasal disease and overall health status in CF.
引用
- Pingree G, Bentan M, Fitzpatrick T, et al. Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis. Int Forum Allergy Rhinol. 2024. PMID: 38958588. doi:10.1002/alr.23400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。